Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Crizotinib in c-MET Mutation Metastatic/Recurrent/Persistent Endometrial Cancer

NCT04030429 is registered in ClinicalTrials.gov with National Cheng-Kung University Hospital as lead sponsor.

NCT NCT04030429
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04030429 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Crizotinib in c-MET Mutation Metastatic/Recurrent/Persistent Endometrial Cancer
Lead sponsor
National Cheng-Kung University Hospital
Phase
Phase 2
Overall status
Terminated
Start date
September 1, 2019
Completion date
June 1, 2025
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial cancer recurrent